Bladder cancer is characterized by a high recurrence rate, with limited therapeutic options available. There is a need to discover new therapeutic targets and approaches to overcome this.
Tumor-associated macrophages (TAMs), located within the tumor microenvironment (TME), are involved in immunosuppression, metastasis, chemoresistance and angiogenesis. Reprogramming TAMs intratumorally by targeting glutamine metabolism may provide a robust antitumor effect.
Asieris Pharmaceuticals Co. Ltd. has described indole phthalocyanine compounds acting as fluorescence imaging agents with high contrast reported to be useful for the diagnosis of bladder cancer.
CD276-based immunotherapy strategies have demonstrated potent antitumor activity and feasibility for clinical application in solid tumors. In urothelial bladder cancer, CD276 is also aberrantly expressed. However, the exact role of CD276 in bladder cancer tumorigenesis and its potential clinical significance remain unexplored.
Bladder cancer is among the top 10 malignant tumors, still with a high mortality rate. There is a need for reliable biomarkers for early diagnosis of the disease. Proximity extension analysis (PEA) is a method that uses a quantitative PCR readout to analyze protein levels in plasma in longitudinal studies and genomic association studies.
CSPC Pharmaceutical Group Ltd. has received clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with SYH-2039, a highly selective methionine adenosyltransferase 2A (MAT2A) inhibitor, for advanced malignant tumors.
Lantern Pharma Inc. has generated a new class of highly specific and highly potent antibody-drug conjugates (ADCs) with a cryptophycin drug-payload, in collaboration with Bielefeld University.
Researchers from the Institute for Bioengineering of Catalonia (IBEC) and collaborators have successfully treated bladder tumors in mice using urease-powered nanobots. The testing consisted of the administration of 18F-nanorobots to tumor-bearing mice divided into four groups depending on tumor volumes using a group of non-tumor-bearing mice as control. Importantly, the therapy remained in the bladder with only a very small proportion of radioactivity seen in other organs. The results were published in Nature Nanotechnology on Jan. 15, 2024.
Veracyte Inc. revealed plans to buy C2i Genomics Inc. at the J.P. Morgan Health Care Conference in San Francisco on Jan. 8, a move that will significantly expand its portfolio of cancer diagnostic and monitoring assays. The terms include $70 million in Veracyte shares to be paid at closing plus an addition $25 million payable in cash or Veracyte shares over the next two years if C2i achieves certain performance milestones.
